Dicerna Pharma Signs Collaboration Deal with Kyowa Hakko

Dicerna Pharmaceuticals Inc., a Cambridge, Mass.-based RNA interference company, has signed a research collaboration and license agreement with Japan's Kyowa Hakko Kirin Co. Ltd. (TSE: 4151). The deal includes a $4 million up-front cash payment, plus up to $120 million in milestone payments. It also includes an option to expand the scope of the collaboration by adding approximately up to 10 targets under similar terms. Dicerna has raised over $21 million in VC funding from Abingworth Management, Oxford Bioscience Partners and Skyline Ventures.

North AmericaUSBriefs